Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Sept. 7, 2011 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), announced today that Larry Andrews, President and Chief Executive Officer, is presenting at the Rodman & Renshaw Annual Global Investment Conference, which is being held in New York City from September 11-13 at the Waldorf Astoria. Mr. Andrews will provide an update on the Company's drug development activities and plans. Cipher's presentation will take place on Monday, September 12, 2011 at 4:30 pm ET in the Metropolitan East room.

Cipher's presentation will be available at www.cipherpharma.com.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals is a commercial-stage drug development company focused on commercializing novel formulations of successful, currently marketed molecules using advanced drug delivery technologies. Cipher's strategy is to in-license products that incorporate proven drug delivery technologies and advance them through the clinical development and regulatory approval stages, after which the products are out-licensed to international partners. Because Cipher's products are based on proven technology platforms applied to currently marketed drugs, they are expected to have lower approval risk, shorter development timelines and significantly lower development costs. The Company's lead compound is being marketed in the United States by Kowa Pharmaceuticals America under the label Lipofen®. Cipher's second product, an extended-release version of the pain reliever tramadol, has received final FDA approval and is expected to be launched by Vertical Pharmaceuticals in the United States in Q3 2011. The Company's third product, a novel formulation of the acne treatment isotretinoin, recently completed its final Phase III safety study.

Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and has approximately 24 million shares outstanding.  For more information, please visit www.cipherpharma.com.